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Abstract
Background: More than 90% of Congenital Adrenal Hyperplasia (CAH) cases are associated with
mutations in the 21-hydroxylase gene (CYP21A2) in the HLA class III area on the short arm of
chromosome 6p21.3. In this region, a 30 kb deletion produces a non functional chimeric gene with
its 5' and 3' ends corresponding to CYP21A1P pseudogene and CYP21A2, respectively. To date, five
different CYP21A1P/CYP21A2 chimeric genes have been found and characterized in recent studies.
In this paper, we describe a new CYP21A1P/CYP21A2 chimera (CH-6) found in an Italian CAH
patient.
Methods: Southern blot analysis and CYP21A2 sequencing were performed on the patient. In
addition, in order to isolate the new CH-6 chimeric gene, two different strategies were used.
Results: The CYP21A2 sequencing analysis showed that the patient was homozygote for the
g.655C/A>G mutation and heterozygote for the p.P30L missense mutation. In addition, the
promoter sequence revealed the presence, in heterozygosis, of 13 SNPs generally produced by
microconversion events between gene and pseudogene. Southern blot analysis showed that the
woman was heterozygote for the classic 30-kb deletion producing a new CYP21A1P/CYP21A2
chimeric gene (CH-6). The hybrid junction site was located between the end of intron 2
pseudogene, after the g.656C/A>G mutation, and the beginning of exon 3, before the 8 bp deletion.
Consequently, CH-6 carries three mutations: the weak pseudogene promoter region, the p.P30L
and the g.655C/A>G splice mutation.
Conclusion: We describe a new CYP21A1P/CYP21A2 chimera (CH-6), associated with the HLA-
B15, DR13 haplotype, in a young Italian CAH patient.
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Background
Congenital Adrenal Hyperplasia (CAH) is an autosomal
recessive disorder mainly caused by defects in the steroid
21-hydroxylase gene (CYP21A2). Steroid 21-hydroxylase
is a microsomal cytochrome P450 required for the synthe-
sis of cortisol and aldosterone but not for the synthesis of
sex steroids. The reduced synthesis of cortisol and aldos-
terone leads to excessive androgen production [1].
CAH includes a wide spectrum of clinical manifestations.
Milder forms are referred to as Nonclassic (NC) or late-
onset CAH [2]. Patients with the severe classic disease
form are classified as either salt-wasting (SW) or simple-
virilising (SV) depending on whether or not synthesis of
the salt retaining hormone, aldosterone, is affected [3].
The gene encoding 21-hydroxylase, CYP21A2, is located
in the HLA class III region on the short arm of chromo-
some 6p21.3 [4]. In this region, four tandemly arranged
genes – serine/threonine Kinase RP, complement C4, ster-
oid 21-hydroxylase CYP21, and tenascin TNX – are organ-
ized as a genetic unit designated as a RCCX module. In a
RCCX bimodular haplotype, duplication of the RCCX
module occurs and the orientation of genes, from tel-
omere to centromere, is: RP1-C4A-CYP21A1P-TNXA-RP2-
C4B-CYP21A2-TNXB. The three pseudogenes, CYP21A1P-
TNXA and RP2, located between the two C4 loci, do not
encode functional proteins [5,6].
In the Caucasian population, bimodular and monomod-
ular RCCX organizations are present in about 69% and
17% of chromosome 6, respectively, while trimodular
RCCX haplotypes have a frequency of about 14% [7]. The
CYP21A2 gene and CYP21A1P pseudogene each contain
10 exons spaced over 3.1 Kb, their nucleotide sequences
are 98% identical in exons and approximately 96% iden-
tical in introns [8]. Intergenic recombinations are respon-
sible for 95% of the mutations associated with 21-
hydroxylase deficiency; the remaining 5% of mutations
do not appear to be the result of gene conversion events
[9,10]. Among the intergenic recombinations, approxi-
mately 75% is represented by mutations normally present
in the pseudogene and possibly transferred to the func-
tional gene by microconversion events [11]. The remain-
ing 20%–25% of mutations are CYP21A2 gene deletions
or CYP21A1P/CYP21A2 chimeric genes. In fact, the 26 or
32 Kb deletion (depending on whether C4B is the long or
short gene), involving the 3' end of CYP21A1P, all of the
C4B gene, and the 5' end of CYP21A2, produces a single
non functional chimeric gene with its 5' and 3' ends cor-
responding to CYP21A1P  and  CYP21A2, respectively
[1,11]. To date, five different chimeric CYP21A1P/
CYP21A2  genes have been found and characterized in
recent studies [12-16]. In this paper, we describe a new
CYP21A1P/CYP21A2 chimeric gene (CH-6) found in an
Italian patient suffering from a severe form of CAH.
Methods
Patients
The patient is the first daughter of non consanguineous
parents of Italian origin. No family history of CAH, of vir-
ilisation in female family members or of impaired fertility
was reported. Pregnancy and delivery were uneventful and
birth weight and length were normal (3400 g, 51 cm).
Diagnosis of CAH was suspected due to genital virilisation
(Prader IV). Thus, hormonal evaluation and kariotype
were requested. Plasma levels of Na and K were 124 mEq/
L and 6.2 mEq/L, respectively, while 17-OHP plasma
value, on fourth day of life, was 223 nmol/L. Kariotype
showed a normal female pattern (46, XX). Therapy with
betamethasone and fluorohydrocortisone was started on
the 11th day. No vomiting or other clinical signs of salt
wasting were shown before onset of substitutive therapy.
Clitoromegaly was corrected at 4 yr of age and hydrocor-
tisone therapy was started at 6 yr. The patient showed a
normal pubertal development with menarche at 14 yr and
she underwent vaginoplasty at 17 yr. She married at 26 yr
with a healthy Italian male and she was pregnant at 29 yr.
Molecular analysis of CYP21A2 gene
Informed consent for genetic study was obtained, it was in
compliance with the Helsinki Declaration and was
approved by Catholic University Ethics Committee (Ref-
erence Number: P6242008).
Genomic DNA was isolated from peripheral blood sam-
ples using High Pure PCR Template Preparation Kits
(Roche Diagnostic, USA), quantified by spectrophotome-
ter at 260 nm and stored at -20°C until use. In addition,
since the patient decided to undergo an amniocentesis at
18th week of gestation, a DNA sample was extracted from
amniotic fluid cells.
Two genomic DNA fragments, spanning from the 5'
region to exon 6 (FRAG 1) and from exon 6 to 3'region
(FRAG 2) of the active CYP21A2  gene, were amplified
using two sets of specific primers, as previously described
[17]. In addition, the CYP21A2  promoter region was
amplified using the primers: PROM-F 5'-gca ggg act gcc att
ttc tc-3' (nucleotides 87034–87053; GeneBank accession
AL049547) and PROM-R 5'-agc agg gag tag tct ccc aag-
3'(nucleotides 85935–85955; GeneBank accession
AL049547).
PCR-amplified fragments were directly sequenced using
BigDye Terminator Cycle Sequencing kit v3.1(Applied
Biosystems, USA) and ABI 3100 Avant Genetic AnalyserBMC Medical Genetics 2009, 10:72 http://www.biomedcentral.com/1471-2350/10/72
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(Applied Biosystems, USA) according to manufacturer's
instructions.
The results were analysed using the SeqScape v2.5 soft-
ware package (Applied Biosystems, USA). The CYP21A2
sequence references were: NCBI-AL049547 and NC-
000006.
HLA typing
HLA-B and HLA-DRB1 genotypes were determined using
a semi-automated, commercially available reverse dot-
blot method (Inno-lipa, Innogenetics, Gent, Belgium),
according to the manufacturer's instructions. Reaction
patterns were interpreted using INNO-LiPA software.
CYP21/C4 haplotyping
Leukocyte DNA was digested with TaqI restriction enzyme
and Southern blotting studies were conducted as previ-
ously described [18]. Blots were probed with a mixture of
two fragments: a 500-bp BamHI-KpnI 5' fragment of C4
cDNA (pAT-A clone) and a 3.1-Kb genomic EcoRI-BamHI
fragment of the 5.5-Kb BglII-BamHI fragment encompass-
ing the entire CYP21A2 gene cloned in the BamHI site of
bluscript SK+ plasmid [18,19].
Band ratios were measured by laser densitometry (Ultros-
can XL laser densitometer; Pharmacia LKB).
Isolation of CYP21A1P/CYP21A2 chimeric gene
In order to isolate the chimeric CYP21A1P/CYP21A2
allele, two different strategies were used. The first was an
allele specific PCR performed using the primers: PROMPS
5'-cca ggt cgg ggc gga cac cc-3' (nucleotides 433–452;
GeneBank accession NC_000006.10 [region:
32.080.697...32.084.739]) and PROM-R (nucleotides
85935–85955; GeneBank accession AL049547). The
PROMPS forward primer was specific for a CYP21A1P
pseudogene 5' sequence while the reverse PROM-R primer
was specific for exon 3 of the CYP21A2 active gene. The
PCR fragment, spanning from the 5' region to exon 3 of
the chimeric gene, was directly sequenced.
The second strategy was the amplification (Expand Long
Template PCR System, Roche Diagnostic, USA), using
CYP779f and Tena36F2 primers, of a 6.2Kb fragment
encompassing the 5'-end of the CYP21A2 gene and exon
36 of the TNXB gene [20]. After amplification, 700 ng of
the PCR product was incubated at 65°C for 2 h with 10 U
of Taq I restriction enzyme. The completely digested PCR
product was analyzed by electrophoresis on a 1.2% agar-
ose gel to evaluate the presence of the 3.7- and 3.2-Kb
fragments produced by the active CYP21A2 gene and the
chimeric CYP21A1P/CYP21A2 gene, respectively [20]. The
3.2 Kb fragment including the whole CYP21A1P/CYP21A2
chimera [being generated by the Taq I cutting at 86870
position (GeneBank accession AL049547), corresponding
to -209 C nucleotide in the CYP21A1P promoter region,
and at 83662 position (GeneBank accession AL049547)
within 5' region of TNXB gene] was isolated from agarose
gel (QIAEX II Gel Extraction Kit, Qiagen, Hilden, Ger-
many) and sequenced using internal primers (available
on request). In order to confirm the obtained results the
6.2 kb fragment was cloned into the pGEM-T vector sys-
tem (Promega, Madison, WI, USA) and the identified
clone was directly used as template for DNA sequencing.
Results
Molecular analysis of CYP21A2 gene
The CYP21A2 sequencing analysis showed that the patient
was homozygote for the g.655C/A>G mutation in intron
2 and heterozygote for the p.P30L missense mutation in
exon 1. In addition, the promoter sequence revealed the
presence, in heterozygosis, of 13 variants (g.-306G>C, g.-
295T>C, g.-294A>C, g.-283A>G, g.-281T>G, g.-210T>C,
g.-199C>T, g.-190insT, g.-126C>T, g.-113G>A, g.-
110T>C, g.-103A>G and g.-4C>T) which are generally the
result of microconversion events between gene and pseu-
dogene. In this first sequencing analysis step, we were
unable to perform the complete nucleotide analysis of
intron 2 since the electropherogram showed various
frameshift mutations resulting in two overlapping
sequences.
The same problem was present when the fetus'CYP21A2
sequence was analyzed. However, the results showed that
the fetus' DNA carried, in heterozigiosis, both the g.656C/
A>G and p.P30L mutations in addition to the 13 variants
in the promoter region.
Finally, the patient's husband resulted wild type for the
CYP21A2 sequencing analysis.
HLA typing
The results of HLA-DRB and HLA-B genotypes were as fol-
lows: patient: HLA-B*35/44 HLA-DRB1*01/13; husband:
HLA-B*15/51 HLA-DRB1*11/13; male fetus: HLA-B*15/
44 HLA-DRB1*01/13. These results confirmed the correct
segregation of HLA loci.
CYP21/C4 haplotyping
The Southern blot results are shown in Fig. 1 and were
interpreted as follows: 1) the fetus' father (lane 1) carried
two bimodular chromosomes with a total of two
CYP21A2 genes (3.7 kb and 2.5 kb bands), two CYP21A1P
pseudogenes (3.2 kb and 2.4 kb bands), two long telom-
eric C4 genes(7.0 kb band) and two short non-telomeric
C4 genes (5.4 kb band); the patient (lane 2) carried a
chromosome with a normal bimodular structure (one
CYP21A2 gene, one CYP21A1P pseudogene, one long tel-
omeric C4 gene and one long non-telomeric C4 gene cor-BMC Medical Genetics 2009, 10:72 http://www.biomedcentral.com/1471-2350/10/72
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responding to 6.4 kb band) and a chromosome with the
classic 30 Kb deletion (as shown by decreased intensities
of 6.4 kb band, corresponding to the C4B gene, and of 3.7
kb and 2.4 kb bands corresponding to the 5' section of the
CYP21A2  active gene and to the 3' fragment of the
CYP21A1P  pseudogene, respectively); finally, the fetus
(lane 3) inherited from the father a wild type bimodular
chromosome with a short non-telomeric C4  gene and
from the mother the chromosome with the 30 kb deletion
(as shown by the absence of the 6.4 kb band and by the
decreased intensities of 3.7 kb and 2.4 kb bands).
Sequence of CYP21A1P/CYP21A2 chimeric gene
The 6.2 Kb long PCR digested with TaqI enzyme[20] com-
bined with cloning and sequencing of 3.2 Kb fragment
allowed to prove the existence of the new chimeric gene.
In fact, the sequencing analysis showed that CH-6 gene
have a CYP21A1P-like sequence up to 656 nucleotide of
intron 2 while the remaining exons/intons have a wild
type CYP21A2 sequence (Fig. 2).
Discussion
The chimeric CYP21A1P/CYP21A2  gene is the conse-
quence of the 26 or 32 Kb deletion including the complete
XA,  RP2, and C4B  genes and the partial sequences of
CYP21A1P and CYP21A2 genes [20].
The possible cause of the chimera formation is the pres-
ence of specific sequences, such as Chi-like and tandem-
repetitive minisatellite consensus, which play a role in
promoting genetic recombination [21]. In particular, it
has been pointed out that the chi-like sequence GCT-
GGGG is present several times in the intronic regions of
CYP21A2 and CYP21A1P genes [22]. However, the high
degree of sequence homology of RP1-C4A-CYP21A1P-XA-
RP2-C4B-CYP21A2-TNXB  genes arranged in tandem,
seems to be the most probable way to increase the chance
of misalignment at meiosis to generate genetic recombi-
nation in the 6p21.3 chromosome area [23].
To date, five different chimeric CYP21A1P/CYP21A2 genes
have been found and characterized [12-16] (Fig. 3). Three
of them, found in ethnic Chinese (Taiwanese), are named
CH-1, CH-2, and CH-3 [12-14]. In these molecules, the
deletion g.707–724delGAGACTAC in exon 3 leads to a
frameshift mutation which forms a TGA stop codon
downstream 830 nucleotide producing a truncated pro-
tein.
CH-4 chimera was found in a Caucasian NC-CAH patient
[15] and it is probably the same one earlier reported by
Killeen et al. [24]. CH-4 junction site was located between
the end of exon 1 and the beginning of intron 2, conse-
quently, the resulting hybrid gene differs from the func-
tional gene only for the presence of two deleterious
mutations: the weak promoter region of the pseudogene
and the p.P30L missense mutation in exon 1. Finally, CH-
5 chimera, associated with the HLA-B47, DR7 haplotype,
was described by White et al. [16] and results very com-
mon among CAH patients of Caucasian origin.
In this paper, we report a new CYP21A1P/CYP21A2 chi-
mera (CH-6) found in an Italian woman suffering from
salt-wasting form of CAH. The hybrid junction site was
located between the end of intron 2 pseudogene, after the
g.656C/A>G mutation, and the beginning of exon 3,
before the 8 bp deletion. Consequently, CH-6 carries three
mutations: the weak pseudogene promoter region, the
p.P30L in exon 1 and the g.655C/A>G splice mutation in
intron 2 (Fig. 3). Since the patient carried a second
CYP21A2 allele with the g.656C/A>G mutation, her clini-
cal severe phenotype was determined by the homozygote
status for this mutation. Unfortunately, it was not possi-
ble to perform a more extensive familiar genetic study and
therefore we can not determine if the patient inherited the
new CH-6 chimeric gene from one of her parents.
However, our molecular CAH prenatal diagnosis showed
that the fetus inherited the new chimeric gene from his
mother and a wild type CYP21A2 allele from his father, as
also confirmed by HLA typing.
Conclusion
In conclusion, we describe a new CYP21A1P/CYP21A2
chimera (CH-6), associated with the HLA-B15, DR13 hap-
lotype, in a young Italian CAH patient.
Southern blot analysis Figure 1
Southern blot analysis. Taq I restriction patterns of 
genomic DNA hybridized to a mixture of the CYP21A2 and 
C4 cDNA probes. Fa: father, Mo: mother. For pattern analy-
sis see the text in results section.BMC Medical Genetics 2009, 10:72 http://www.biomedcentral.com/1471-2350/10/72
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Sequence of the new chimeric gene Figure 2
Sequence of the new chimeric gene. Sequence of CH-6 chimera from +1 nucleotide (exon 1) to +721 nucleotide (exon 3). 
Nucleotides were numbered starting from ATG. The lines showed: the amino acid sequence of CYP21A2 gene (M13936), the 
CYP21A2 nucleotide sequence (M13936), the CYP21A1P nucleotide sequence (M13935) and the CH-6 nucleotide sequence. 
Only nucleotide differences between CYP21A1P or CH-6 and CYP21A2 active gene are shown under corresponding nucleotides 
in CYP21A2 gene.BMC Medical Genetics 2009, 10:72 http://www.biomedcentral.com/1471-2350/10/72
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